$11.82
1.55%
Nasdaq, Oct 10, 10:14 pm CET
ISIN
US71722W1071
Symbol
PHAT

Phathom Pharmaceuticals Inc Stock price

$11.82
-0.50 4.06% 1M
+7.71 187.59% 6M
+3.70 45.57% YTD
-3.89 24.76% 1Y
+1.64 16.11% 3Y
-28.40 70.61% 5Y
-12.78 51.95% 10Y
-12.78 51.95% 20Y
Nasdaq, Closing price Fri, Oct 10 2025
+0.18 1.55%
ISIN
US71722W1071
Symbol
PHAT
Industry

Key metrics

Basic
Market capitalization
$838.6m
Enterprise Value
$1.3b
Net debt
$424.1m
Cash
$149.6m
Shares outstanding
70.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.4 | 4.8
EV/Sales
11.1 | 7.3
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-67.0%
Return on Equity
131.8%
ROCE
-169.8%
ROIC
-
Debt/Equity
-1.4
Financials (TTM | estimate)
Revenue
$114.0m | $173.0m
EBITDA
$-268.3m | $-164.9m
EBIT
$-269.0m | $-187.0m
Net Income
$-330.2m | $-232.1m
Free Cash Flow
$-274.9m
Growth (TTM | estimate)
Revenue
1,049.6% | 213.1%
EBITDA
-6.4% | 40.4%
EBIT
-6.4% | 32.6%
Net Income
-11.1% | 30.6%
Free Cash Flow
-26.7%
Margin (TTM | estimate)
Gross
86.9%
EBITDA
-235.2% | -95.3%
EBIT
-235.9%
Net
-289.5% | -134.2%
Free Cash Flow
-241.0%
More
EPS
$-4.6
FCF per Share
$-3.9
Short interest
30.7%
Employees
427
Rev per Employee
$130.0k
Show more

Is Phathom Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,999 stocks worldwide.

Phathom Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Phathom Pharmaceuticals Inc forecast:

Buy
87%
Hold
13%

Financial data from Phathom Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
114 114
1,050% 1,050%
100%
- Direct Costs 15 15
658% 658%
13%
99 99
1,147% 1,147%
87%
- Selling and Administrative Expenses 333 333
52% 52%
292%
- Research and Development Expense 36 36
16% 16%
31%
-268 -268
6% 6%
-235%
- Depreciation and Amortization 0.73 0.73
1% 1%
1%
EBIT (Operating Income) EBIT -269 -269
6% 6%
-236%
Net Profit -330 -330
11% 11%
-290%

In millions USD.

Don't miss a Thing! We will send you all news about Phathom Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Phathom Pharmaceuticals Inc Stock News

Positive
Seeking Alpha
6 days ago
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Neutral
GlobeNewsWire
6 days ago
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence Appointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company fo...
Neutral
GlobeNewsWire
about 2 months ago
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:
More Phathom Pharmaceuticals Inc News

Company Profile

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Head office United States
CEO Steven Basta
Employees 427
Founded 2018
Website www.phathompharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today